Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
NUC01, Placebo to NUC01
Dr. Falk Pharma GmbH
primary sclerosing cholangitis (PSC)
1 trial -
NUT01
Dr. Falk Pharma GmbH
Primary Sclerosing Cholangitis (PSC)
1 trial -
Orodispersible tablet, BUL03, Jorveza 1 mg orodispersible tablets
Dr. Falk Pharma GmbH
eosinophilic esophagitis
1 trial -
BUL02, Placebo orodispersible tablets, BUL03
Dr. Falk Pharma GmbH
Prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection
1 trial -
Budenofalk 4 mg Zäpfchen, placebo to test
Dr. Falk Pharma GmbH
Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
1 trial -
NAT01, NAT03, Placebo film coated tablets, NAT02
Dr. Falk Pharma GmbH
Idiopathic or Diabetic Gastroparesis
1 trial -
Placebo matching with ZED1227 capsules of Dr. Falk Pharma GmbH, CEC02, CEC03
Dr. Falk Pharma GmbH
Celiac Disease
1 trial -
A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects
Dr. Falk Pharma GmbH
Idiopathic or diabetic gastroparesis
1 trial -
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)
Dr. Falk Pharma GmbH
Primary Sclerosing Cholangitis (PSC)
1 trial -
Evaluation of the Effect of Food, Itraconazole, and Rifampicin on the Single-Dose Pharmacokinetics of Naronapride.
Dr. Falk Pharma GmbH
No medical condition.
1 trial -
Evaluation of the Effect of Itraconazole, Quinidine and Rifampicin on the Single-Dose Pharmacokinetics of ZED1227
Dr. Falk Pharma GmbH
No medical condition.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources